1
|
Tropeano A, Corica D, Curatola S, Li Pomi A, Casto C, Alibrandi A, Pepe G, Aversa T, Wasniewska M. The effect of obesity-related allostatic changes on cardio-metabolic risk in euthyroid children. J Endocrinol Invest 2023; 46:285-295. [PMID: 35986868 DOI: 10.1007/s40618-022-01899-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Accepted: 08/09/2022] [Indexed: 01/25/2023]
Abstract
PURPOSE The hormonal thyroid changes related to obesity, even when in the euthyroid state, may contribute to the unfavorable cardio-metabolic profile of obese patients. In this retrospective study, we aim to investigate the biochemical thyroid changes and the association between serum TSH, FT4, FT3 and cardio-metabolic risk factors in euthyroid obese youths. METHODS Four hundred ninety-one Caucasian euthyroid obese children and adolescents aged 9.93 ± 2.90 years were recruited. Each patient underwent clinical and auxological examination and laboratory workup including an OGTT and the measurement of thyroid function and lipid profile. Homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride to high-density lipoprotein cholesterol ratio, total cholesterol to HDL ratio, atherogenic index of plasma, insulinogenic index, area under the glucose and insulin curves were calculated. RESULTS We found that TSH was positively correlated with BMI-SDS values and significantly associated with hypercholesterolemia and hyperinsulinemia; FT4 resulted negatively correlated with BMI-SDS; FT3 was positively correlated with BMI-SDS and the area under the curve of insulin and negatively correlated with HDL. FT3 and FT4 resulted significantly associated with severe obesity. In addition, children with high-normal TSH values showed higher triglyceride to high-density lipoprotein cholesterol ratio values than those with normal TSH levels. CONCLUSIONS Our data showed that thyroid hormones could influence obesity, lipid and glycemic parameters in euthyroid youths. These findings could carry implications regarding optimal TSH levels in obese children and confirm the importance of evaluating the thyroid function as possible adjunctive cardio-metabolic risk factor related to obesity.
Collapse
Affiliation(s)
- A Tropeano
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - D Corica
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - S Curatola
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - A Li Pomi
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - C Casto
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - A Alibrandi
- Department of Economics, University of Messina, 98122, Messina, Italy
| | - G Pepe
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - T Aversa
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy
| | - M Wasniewska
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", Unit of Pediatrics, University of Messina, via Consolare Valeria, 98124, Messina, Italy.
| |
Collapse
|
2
|
Pepe G, Appierdo R, Carrino C, Ballesio F, Helmer-Citterich M, Gherardini PF. Artificial intelligence methods enhance the discovery of RNA interactions. Front Mol Biosci 2022; 9:1000205. [PMID: 36275611 PMCID: PMC9585310 DOI: 10.3389/fmolb.2022.1000205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 09/20/2022] [Indexed: 11/13/2022] Open
Abstract
Understanding how RNAs interact with proteins, RNAs, or other molecules remains a challenge of main interest in biology, given the importance of these complexes in both normal and pathological cellular processes. Since experimental datasets are starting to be available for hundreds of functional interactions between RNAs and other biomolecules, several machine learning and deep learning algorithms have been proposed for predicting RNA-RNA or RNA-protein interactions. However, most of these approaches were evaluated on a single dataset, making performance comparisons difficult. With this review, we aim to summarize recent computational methods, developed in this broad research area, highlighting feature encoding and machine learning strategies adopted. Given the magnitude of the effect that dataset size and quality have on performance, we explored the characteristics of these datasets. Additionally, we discuss multiple approaches to generate datasets of negative examples for training. Finally, we describe the best-performing methods to predict interactions between proteins and specific classes of RNA molecules, such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs), and methods to predict RNA-RNA or RNA-RBP interactions independently of the RNA type.
Collapse
Affiliation(s)
- G Pepe
- Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
- *Correspondence: G Pepe, ; M Helmer-Citterich,
| | - R Appierdo
- Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
| | - C Carrino
- PhD Program in Cellular and Molecular Biology, Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
| | - F Ballesio
- PhD Program in Cellular and Molecular Biology, Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
| | - M Helmer-Citterich
- Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
- *Correspondence: G Pepe, ; M Helmer-Citterich,
| | - PF Gherardini
- Department of Biology, University of Rome “Tor Vergata”, Rome, Italy
| |
Collapse
|
3
|
Vanni S, Gori L, Coppa A, Nazerian P, Giannasi G, Ruggiano G, De Curtis E, Baldini A, Pepe G, Magazzini S. Prevalence of pulmonary embolism among patients presenting to emergency department for hemoptysis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Although hemoptysis is a well known symptom of presentation of pulmonary embolism (PE), and it is included in different diagnostic scores for PE, the prevalence of PE in patients with hemoptysis and the yield of evidence based PE diagnostic pathway in these patients has not been specifically investigated.
Objectives
To determine the prevalence of PE and the yield (n° of positive tests/n° of tests), the efficiency (the proportion of patients in whom PE could be considered to be excluded) and the failure rate (the false negative rate) of the classic diagnostic algorithm for PE in patients with hemoptysis.
Methods
Unselected patients presenting with hemoptysis to 7 italian EDs were prospectively enrolled in a diagnostic multicenter study. Pre-test clinical probability for PE was assessed using the 2-level Wells score and the results of D-dimer testing using age-adjusted cutoffs. Presence of PE was evaluated by CT pulmonary angiogram (CTPA), when ordered as part of the clinical assessment by the treating ED physician, or by one month follow-up data.
Results
Out of 327 adult patients presenting to ED with hemoptysis, 15 (4.6%) were excluded because of diagnostic protocol violation and absence of one month follow-up. Among 312 included patients, PE was detected at presentation in 15 patients (4.8%; 95% confidence interval [CI]: 2.72–7.81%). During follow-up, 5 patients died (1.6%; 95% CI: 0.52%-3.7%) not due to PE. Among 165 patients with a “likely” score or a high D-dimer, 13 (7.9%; 95% CI: 4.72–13.8%) had PE. The efficiency was 32.8% and the failure rate was 1.7% in patients tested by D-dimer.
Conclusions
PE seems an uncommon cause of hemoptysis among patients presenting to the ED and the yield of classic diagnostic algorithm is low. PE-screening in patients with hemoptysis deserves further investigation aimed at improving the diagnostic yield.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Vanni
- San Giuseppe Hospital , Empoli , Italy
| | - L Gori
- San Giuseppe Hospital , Empoli , Italy
| | - A Coppa
- San Giuseppe Hospital , Empoli , Italy
| | - P Nazerian
- Careggi University Hospital , Florence , Italy
| | - G Giannasi
- AUSL Toscana Centre, Emergency Department , Florence , Italy
| | - G Ruggiano
- AUSL Toscana Centre, Emergency Department , Florence , Italy
| | - E De Curtis
- St. Stephen Hospital, Emergency Department , Prato , Italy
| | - A Baldini
- St. Stephen Hospital, Emergency Department , Prato , Italy
| | - G Pepe
- USL Toscana Northwest, Emergency Department , Viareggio , Italy
| | - S Magazzini
- AUSL Toscana Centre, Emergency Department , Florence , Italy
| |
Collapse
|
4
|
Ziogas D, Agiannitopoulos K, Pepe G, Potska K, Tsaousis G, Apostolopoulou D, Tsoulos N, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Giassas S, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Psyrri A, Koumarianou A, Papadimitriou C, Papadopoulou E, Nasioulas G. 1709P Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Fransvea P, Costa G, Pepe G, La Greca A, Magalini S, Puccioni C, d'Agostino L, Altieri G, Borello A, Cozza V, Sganga G. Acute intestinal ischemia in patients with COVID-19: single-centre experience and literature review. Eur Rev Med Pharmacol Sci 2022; 26:1414-1429. [PMID: 35253199 DOI: 10.26355/eurrev_202202_28135] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Acute Intestinal ischemia (AII) may involve the small and/or large bowel after any process affecting intestinal blood flow. COVID-19-related gastrointestinal manifestations, including AII, have been attributed to pharmacologic effects, metabolic disorders in ICU patients and other opportunistic colonic pathogens. AII in COVID-19 patients may be due also to "viral enteropathy" and SARS-CoV-2-induced small vessel thrombosis. A critical appraisal of personal experience regarding COVID-19 and AII was carried out comparing this with a systematic literature review of published series. PATIENTS AND METHODS A retrospective observational clinical cohort study and a systematic literature review including only COVID-19 positive patients with acute arterial or venous intestinal ischemia were performed. The primary endpoint of the study was the mortality rate. Secondary endpoints were occurrence of major complications and length of hospital stay. RESULTS Patient mean age was 62.9±14.9, with a prevalence of male gender (23 male, 72% vs. 9 female, 28%). The mean Charlson Comorbidity Index was 3.1±2.7. Surgery was performed in 24/32 patients (75.0%), with a mean delay time from admission to surgery of 6.0 ±5.6 days. Small bowel ischemia was confirmed to be the most common finding at surgical exploration (22/24, 91.7%). Acute abdomen at admission to the ED (Group 1) was observed in 10 (31.2%) cases, while 16 (50%) patients developed an acute abdomen condition during hospitalization (Group 2) for SARS-CoV-2 infection. CONCLUSIONS Our literature review showed how intestinal ischemia in patients with SARS-CoV-2 has been reported all over the world. The majority of the patients have a high CCI with multiple comorbidities, above all hypertension and cardiovascular disease. GI symptoms were not always present at the admission. A high level of suspicion for intestinal ischemia should be maintained in COVID-19 patients presenting with GI symptoms or with incremental abdominal pain. Nevertheless, a prompt thromboelastogram and laboratory test may confirm the need of improving and fastening the use of anticoagulants and trigger an extended indication for early abdominal CECT in patients with suggestive symptoms or biochemical markers of intestinal ischemia.
Collapse
Affiliation(s)
- P Fransvea
- Emergency Surgery and Trauma - Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Carrizzo A, Basilicata MG, Pepe G, Ciccarelli M, Di Pietro P, Campiglia P, Vecchione C. A novel natural-derived pentameric peptide protects from angiotensin-evoked high blood pressure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Arterial hypertension is the most important risk factor for cardiovascular diseases, myocardial infarction, heart failure, renal failure and peripheral vascular disease. In the last decade, milk-derived bioactive peptides have attracted attention for their beneficial cardiovascular properties.
Methods
Here we combined in-vitro chemical assay such as LC-MS/MS analysis of buffalo ice cream, ex-vivo vascular studies evaluating endothelial and smooth muscle responses using pressure myograph, and translational assay testing in-vivo the vascular actions of PG1 administration in murine models.
Results
We demonstrate that a novel buffalo ice-cream-derived pentapeptide “QKEPM”, namely PG1, is a stable peptide that can be obtained at higher concentration after gastro-intestinal digestions (GID) of buffalo ice-cream (BIC). It owns potent vascular effect in counteract the effects of angiotensin II-evoked vasoconstriction and high blood pressure levels. Its effects are mediated by the inhibitory effect on AT1 receptor leading to a downregulation of p-ERK½/Rac1-GTP and consequent inactivation of NADPH oxidase activity.
Conclusions
These results strongly candidate PG1, as a novel bioactive peptide for the prevention and management of hypertension, thus expanding the armamentarium of preventive strategies aimed at reducing the incidence and progression of hypertension and its related cardiovascular complications.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): University
Collapse
Affiliation(s)
| | - M G Basilicata
- University of Salerno, Department of Pharmacy, Salerno, Italy
| | - G Pepe
- University of Salerno, Department of Pharmacy, Salerno, Italy
| | | | | | - P Campiglia
- University of Salerno, Department of Pharmacy, Salerno, Italy
| | | |
Collapse
|
7
|
Russo MT, De Luca G, Palma N, Leopardi P, Degan P, Cinelli S, Pepe G, Mosesso P, Di Carlo E, Sorrentino C, Musiani P, Crebelli R, Bignami M, Dogliotti E. Oxidative Stress, Mutations and Chromosomal Aberrations Induced by In Vitro and In Vivo Exposure to Furan. Int J Mol Sci 2021; 22:9687. [PMID: 34575853 PMCID: PMC8465244 DOI: 10.3390/ijms22189687] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/04/2021] [Accepted: 09/05/2021] [Indexed: 11/17/2022] Open
Abstract
Furan is a volatile compound that is formed in foods during thermal processing. It is classified as a possible human carcinogen by international authorities based on sufficient evidence of carcinogenicity from studies in experimental animals. Although a vast number of studies both in vitro and in vivo have been performed to investigate furan genotoxicity, the results are inconsistent, and its carcinogenic mode of action remains to be clarified. Here, we address the mutagenic and clastogenic activity of furan and its prime reactive metabolite cis-2 butene-1,4-dial (BDA) in mammalian cells in culture and in mouse animal models in a search for DNA lesions responsible of these effects. To this aim, Fanconi anemia-derived human cell lines defective in the repair of DNA inter-strand crosslinks (ICLs) and Ogg1-/- mice defective in the removal of 8-hydroxyguanine from DNA, were used. We show that both furan and BDA present a weak (if any) mutagenic activity but are clear inducers of clastogenic damage. ICLs are strongly indicated as key lesions for chromosomal damage whereas oxidized base lesions are unlikely to play a critical role.
Collapse
Affiliation(s)
- Maria Teresa Russo
- National Centre for Chemical Products, Cosmetics and Consumer Protection, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy;
| | - Gabriele De Luca
- Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy;
| | - Nieves Palma
- Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; (N.P.); (P.L.); (R.C.)
| | - Paola Leopardi
- Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; (N.P.); (P.L.); (R.C.)
| | - Paolo Degan
- IRCCS AOU San Martino, Istituto Nazionale per la Ricerca sul Cancro, 16132 Genoa, Italy;
| | - Serena Cinelli
- European Research Biology Center, Via Tito Speri 12/14, Pomezia, 00071 Rome, Italy;
| | - Gaetano Pepe
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, 01100 Viterbo, Italy; (G.P.); (P.M.)
| | - Pasquale Mosesso
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, 01100 Viterbo, Italy; (G.P.); (P.M.)
| | - Emma Di Carlo
- Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, 66022 Chieti, Italy; (E.D.C.); (C.S.)
- Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, 66022 Chieti, Italy
| | - Carlo Sorrentino
- Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, 66022 Chieti, Italy; (E.D.C.); (C.S.)
- Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, 66022 Chieti, Italy
| | - Piero Musiani
- Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, 66022 Chieti, Italy; (E.D.C.); (C.S.)
| | - Riccardo Crebelli
- Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; (N.P.); (P.L.); (R.C.)
| | - Margherita Bignami
- Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; (N.P.); (P.L.); (R.C.)
| | - Eugenia Dogliotti
- Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; (N.P.); (P.L.); (R.C.)
| |
Collapse
|
8
|
Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021; 527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 02/17/2021] [Accepted: 02/21/2021] [Indexed: 01/01/2023]
Abstract
Pancreatic neuroendocrine tumors (Pan-NETs), are heterogeneous neoplasms, whose incidence and prevalence are increasing worldwide. Pan-NETs are characterized by the expression of somatostatin receptors (SSTs). In particular, SST2 is the most widely distributed SST in NETs, thus representing the main molecular target for somatostatin analogs (SSAs). SSAs are currently approved for the treatment of well-differentiated NETs, and radionuclide-labeled SSAs are used for diagnostic and treatment purposes. SSAs, by binding to SSTs, have been shown to inhibit hormone secretion and thus provide control of hypersecretion symptoms, when present, and inhibit tumor proliferation. After SSA binding to SST2, the fate of the receptor is determined by trafficking mechanisms, crucial for the response to endogenous or pharmacological ligands. Although SST2 acts mostly through G protein-dependent mechanism, receptor-ligand complex endocytosis and receptor trafficking further regulate its function. SST2 mediates the decrease of hormone secretion via a G protein-dependent mechanism, culminating with the inhibition of adenylyl cyclase and calcium channels; it also inhibits cell proliferation and increases apoptosis through the modulation of protein tyrosine phosphatases. Moreover, SST2 inhibits angiogenesis and cell migration. In this respect, the cross-talk between SST2 and its interacting proteins, including Filamin A (FLNA) and aryl hydrocarbon receptor-interacting protein (AIP), plays a crucial role for SST2 signaling and responsiveness to SSAs. This review will focus on recent studies from our and other groups that have investigated the trafficking and signaling of SST2 in Pan-NETs, in order to provide insights into the mechanisms underlying tumor responsiveness to pharmacological treatments.
Collapse
Affiliation(s)
- E Vitali
- Laboratory of Cellular and Molecular Endocrinology, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
| | - S Piccini
- Laboratory of Cellular and Molecular Endocrinology, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
| | - G Trivellin
- Laboratory of Cellular and Molecular Endocrinology, Italy; Laboratory of Pharmacology and Brain Pathology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - V Smiroldo
- Oncology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - E Lavezzi
- Endocrinology and Diabetology Unit Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - A Zerbi
- Department of Biomedical Sciences, Humanitas University, Rozzano, Italy; Pancreas Surgery Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - G Pepe
- Nuclear Medicine Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - A G Lania
- Laboratory of Cellular and Molecular Endocrinology, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy; Endocrinology and Diabetology Unit Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| |
Collapse
|
9
|
Crucitti A, La Greca A, Pepe G, Magalini S, Gui D, Sganga G, Bossola M. Percutaneous cholecystostomy in the treatment of acute cholecystitis: is there still a role? A 20-year literature review. Eur Rev Med Pharmacol Sci 2020; 24:10696-10702. [PMID: 33155228 DOI: 10.26355/eurrev_202010_23428] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Percutaneous cholecystostomy (PC) is used for the treatment of acute cholecystitis in patients with high surgical risk due to the severity of cholecystitis and/or the underlying acute or chronic medical comorbidities. The evidence for this strategy is unclear. MATERIALS AND METHODS We searched PubMed and the Cochrane databases for English-language studies published from January 1979 through December 31, 2019, for randomized clinical trials (RCTs), meta-analyses, systematic reviews, and observational studies. RESULTS The two randomized studies that have compared PC with cholecystectomy (CCY) or conservative treatment have shown that the clinical outcomes did not differ significantly between the groups. Similar results have been found in the large majority of retrospective cohorts or single-center studies that have compared PC with CCY. CONCLUSIONS PC does not seem to offer any benefit compared with CCY in the treatment of acute cholecystitis in patients with high surgical risk due to the severity of cholecystitis and/or the underlying acute or chronic medical comorbidities. A large, prospective, randomized study that compares percutaneous PC and CCY in patients with high surgical risk and/or moderate to severe cholecystitis is warranted.
Collapse
Affiliation(s)
- A Crucitti
- General and Minimally Invasive Surgery Unit, Cristo Re Hospital, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
10
|
Capitanio U, Pepe G, Incerti E, Larcher A, Trevisani F, Lucianò R, Mapelli P, Bettinardi V, Menterisi C, Necchi A, Cascinu S, Bernardi R, Bertini R, Doglioni C, Gianolli L, Salonia A, Picchio M, Montorsi F. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial (NCT03955393). EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35538-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
11
|
Di Pardo A, Pepe G, Capocci L, Marracino F, Amico E, Del Vecchio L, Giova S, Jeong SK, Park BM, Park BD, Maglione V. Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington's disease. Neurobiol Dis 2020; 143:105009. [PMID: 32634578 DOI: 10.1016/j.nbd.2020.105009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 06/10/2020] [Accepted: 06/29/2020] [Indexed: 02/08/2023] Open
Abstract
Emerging evidence indicates that Huntington's disease (HD) may be described as multi-organ pathology. In this context, we and others have contributed to demonstrate that the disease is characterized by an impairment of the homeostasis of gastro-intestinal (GI) tract. Sphingolipids represent a class of molecules involved in the regulation and maintenance of different tissues and organs including GI system. In this study, we investigated whether the alteration of Sphingosine-1-phosphate (S1P) metabolism, previously described in human HD brains and animal models, is also detectable peripherally in R6/2 HD mice. Our findings indicate, for the first time, that sphingolipid metabolism is perturbed early in the disease in the intestinal tract of HD mice and, its modulation by K6PC-5, a selective activator of S1P synthesis, preserved intestinal integrity and homeostasis. These results further support the evidence that modulation of sphingolipid pathways may represent a potential therapeutic option in HD and suggest that it has also the potential to counteract the peripheral disturbances which may usually complicate the management of the disease and affect patient's quality of life.
Collapse
Affiliation(s)
| | - G Pepe
- IRCCS Neuromed, Pozzilli, Italy
| | | | | | - E Amico
- IRCCS Neuromed, Pozzilli, Italy
| | - L Del Vecchio
- IRCCS Neuromed, Pozzilli, Italy; Unità complessa di radiodiagnostica (U.O.C.) POS, University of Foggia, Foggia, Italy
| | - S Giova
- IRCCS Neuromed, Pozzilli, Italy
| | - S K Jeong
- Department of Cosmetic Science, Seowon University, Cheongju, Republic of Korea
| | - B M Park
- NeoPharm USA Inc., Engelwood Cliffs, NJ, USA
| | - B D Park
- Dr. Raymond Laboratories, Inc, Englewood cliffs, NJ, USA
| | | |
Collapse
|
12
|
Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, Maglione V, Crispi S, Di Pardo A. Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's disease. Hum Mol Genet 2020; 28:4012-4021. [PMID: 31630202 DOI: 10.1093/hmg/ddz247] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 10/01/2019] [Accepted: 10/02/2019] [Indexed: 11/14/2022] Open
Abstract
Huntington's disease (HD) has traditionally been described as a disorder purely of the brain; however, evidence indicates that peripheral abnormalities are also commonly seen. Among others, severe unintended body weight loss represents a prevalent and often debilitating feature of HD pathology, with no therapies available. It correlates with disease progression and significantly affects the quality of life of HD patients. Curcumin, a naturally occurring polyphenol with multiple therapeutic properties, has been validated to exert important beneficial effects under health conditions as well as in different pathological settings, including neurodegenerative and gastrointestinal (GI) disorders. Here, we investigated the potential therapeutic action that curcumin-supplemented diet may exert on central and peripheral dysfunctions in R6/2 mice, a well-characterized HD animal model which recapitulates some features of human pathology. Maintenance of normal motor function, protection from neuropathology and from GI dysfunction and preservation of GI emptying and conserved intestinal contractility, proved the beneficial role of life-long dietary curcumin in HD and corroborated the potential of the compound to be exploited to alleviate very debilitating symptoms associated with the disease.
Collapse
Affiliation(s)
- F Elifani
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - E Amico
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - G Pepe
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - L Capocci
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - S Castaldo
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - P Rosa
- Department of Medical Surgical Sciences and Biotechnology, Sapienza University of Rome Polo di Latina, Latina, Italy
| | - E Montano
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy.,Department of Biology, Università degli Studi di Napoli - Federico II, Napoli, Italy
| | - A Pollice
- Department of Biology, Università degli Studi di Napoli - Federico II, Napoli, Italy
| | - M Madonna
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - S Filosa
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy.,IBBR-CNR, Institute of Biosciences and Bioresources Napoli, Italy
| | - A Calogero
- Department of Medical Surgical Sciences and Biotechnology, Sapienza University of Rome Polo di Latina, Latina, Italy
| | - V Maglione
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| | - S Crispi
- IBBR-CNR, Institute of Biosciences and Bioresources Napoli, Italy
| | - A Di Pardo
- Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS), Italy
| |
Collapse
|
13
|
Affiliation(s)
- D Gui
- Emergency Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
| | | | | |
Collapse
|
14
|
Perilli V, Aceto P, Ancona P, De Cicco R, Papanice D, Magalini S, Pepe G, Cozza V, Gui D, Lai C, Sollazzi L. Role of surgical setting and patients-related factors in predicting the occurrence of postoperative pulmonary complications after abdominal surgery. Eur Rev Med Pharmacol Sci 2019; 22:547-550. [PMID: 29424916 DOI: 10.26355/eurrev_201801_14208] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The aim of this retrospective study was to evaluate the role of surgical setting (urgent vs. elective) and approach (open vs. laparoscopic) in affecting postoperative pulmonary complications (PPCs) prevalence in patients undergoing abdominal surgery. PATIENTS AND METHODS After local Ethical Committee approval, 409 patients who had undergone abdominal surgery between January and December 2014 were included in the final analysis. PPCs were defined as the development of one of the following new findings: respiratory failure, pulmonary infection, aspiration pneumonia, pleural effusion, pneumothorax, atelectasis on chest X-ray, bronchospasm or un-planned urgent re-intubation. RESULTS PPCs prevalence was greater in urgent (33%) vs. elective setting (7%) (χ2 with Yates correction: 44; p=0.0001) and in open (6%) vs. laparoscopic approach (1.9%) (χ2 with Yates correction: 12; p=0.0006). PPCs occurrence was positively correlated with in-hospital mortality (Biserial Correlation r=0.37; p=0.0001). Logistic regression showed that urgent setting (p=0.000), Ariscat (Assess Respiratory Risk in Surgical Patients in Catalonia) score (p=0.004), and age (p=0.01) were predictors of PPCs. A cut-off of 23 for Ariscat score was also identified as determining factor for PPCs occurrence with 94% sensitivity and 29% specificity. CONCLUSIONS Patients undergoing abdominal surgery in an urgent setting were exposed to a higher risk of PPCs compared to patients scheduled for elective procedures. Ariscat score fitted with PPCs prevalence and older patients were exposed to a higher risk of PPCs. Prospective studies are needed to confirm these results.
Collapse
Affiliation(s)
- V Perilli
- Department of Anaesthesiology and Intensive Care, A. Gemelli University Hospital Foundation, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Tsaousis G, Tsoulos N, Papadopoulou E, Agiannitopoulos K, Pepe G, Diamantopoulos N, Floros T, Iosifidou R, Markopoulos C, Papazisis K, Venizelos V, Xepapadakis G, Banu E, Eniu D, Stanculeanu D, Ungureanu A, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Multigene panel testing results for hereditary breast cancer in 1325 individuals: Implications for gene selection and considerations for guidelines. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Tsoulos N, Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Kambouri S, Apessos A, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Abstract P4-03-07: Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-03-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGOUND: Hereditary cancer predisposition syndromes are believed to be responsible for approximately 5-10% of all diagnosed cancer cases. In the past, single genes analysis of certain high risk genes was used for the determination of the genetic cause of cancer heritability in certain families. The selection of genes was mainly based on the family history of the individuals analyzed and included only highly associated genes (e.g. the BRCA1 and BRCA2 genes for families with breast cancer history. Nowadays though, the application of Next Generation Sequencing (NGS) technology has facilitated multigene panel analysis and is widely used in clinical practice, for the identification of individuals with cancer predisposition gene mutations.
AIM: The aim of this study was to investigate the extent and nature of mutations in 36 genes implicated in hereditary cancer predisposition in individuals referred for testing in our lab.
MATERIALS & METHODS: In total, 1197 individuals were referred for testing in our lab in the past four years from Greece, Romania and Turkey. The analysis of genes involved in hereditary cancer predisposition was performed using two NGS approaches. The first 451 individuals were analyzed using an amplicon based sequencing method (26 gene panel), while the following 746 individuals were analyzed using a capture based method (33 gene panel). Genomic DNA was enriched for targeted regions of 36 genes involved in hereditary predisposition to cancer included in both versions of the panel (APC, BMPR1A, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, PTEN, RET, SMAD4, STK11, TP53, VHL, ATM, BRIP1, CHEK2, NBN, RAD51C, RAD51D, BARD1, BLM, CHEK1, ABRAXAS1 (FAM175A), MRE11 (MRE11A), NF1, RAD50, RAD51B, XRCC2). Sequencing was carried out using the Illumina NGS technology. Reads were aligned to the reference sequence (GRCh37), and sequence changes were identified and interpreted in the context of a single clinically relevant transcript. The presence of large genomic rearrangements was investigated by computational analysis of NGS results and the use of MLPA for 13 genes. All clinically significant observations were confirmed by orthogonal technologies.
RESULTS: In total, a pathogenic mutation was identified in 259 of the 1197 individuals (21.6%) analyzed while a VUS was identified in 35.7% of the cases. Clinically significant mutations were identified in 29 of the genes analyzed. Concerning the mutation distribution among individuals with positive findings, 44.7% of them were located in BRCA1/2 genes whereas 20.9%, 19.9%, and 14.5% in high, moderate and low risk genes respectively. In addition to BRCA1 and BRCA2 genes other highly mutated genes were CHEK2 (10.6%), PALB2 (7.1%), MUTYH (7.1%) and ATM (4.3%). Of note is that 25 of the 259 positive individuals (9.7%) carried clinically significant mutations in two different genes and 5.8% had a large genomic rearrangement (LGR).
CONCLUSIONS: Our results support the clinical significance of analysis of a panel of genes involved in hereditary cancer predisposition. In our cohort, analysis of this panel allowed for the identification of 8.3% additional pathogenic variants in moderate/low risk genes, enabling personalized management of these individuals.
Citation Format: Tsoulos N, Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Kambouri S, Apessos A, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-03-07.
Collapse
Affiliation(s)
- N Tsoulos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - GN Tsaousis
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - E Papadopoulou
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - K Agiannitopoulos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - G Pepe
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - S Kambouri
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - A Apessos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - N Diamantopoulos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - T Floros
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - R Iosifidou
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - O Katopodi
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - A Koumarianou
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - C Markopoulos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - K Papazisis
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - V Venizelos
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - I Xanthakis
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - G Xepapadakis
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - E Banu
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - DT Eniu
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - S Negru
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - DL Stanculeanu
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - A Ungureanu
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - V Ozmen
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - S Tansan
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - M Tekinel
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - S Yalcin
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| | - G Nasioulas
- GeneKor Medical S.A, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; Athens Naval and Veterans Hospital, Athens, Greece; Euroclinic Group, Athens, Greece; Attikon University Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece; Metropolitan Hospital, Athens, Greece; St. Luke's Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Spitalul Sfantul Constantin Brasov, Brasov, Romania; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; University of Medicine and Pharmacy of Timisoara, Timisoara, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Amethyst Radiotherapy Cluj-Napoca, Cluj, Romania; Faculty of Medicine Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; Private Practice, Fulya Sisli, Turkey; Private Practice, Kavaklidere, Turkey
| |
Collapse
|
17
|
Mosesso P, Piane M, Pepe G, Cinelli S, Chessa L. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP). Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2018; 836:117-123. [DOI: 10.1016/j.mrgentox.2018.05.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2018] [Revised: 04/16/2018] [Accepted: 05/07/2018] [Indexed: 10/17/2022]
|
18
|
Tsoulos N, Apessos A, Agiannitopoulos K, Pepe G, Tsaousis G, Kambouri S, Eniu DT, Ungureanu A, Banu E, Ciule L, Blidaru A, Chiorean A, Stanculeanu DL, Mateescu D, Nasioulas G. Abstract P3-03-03: Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION
Hereditary breast cancer is estimated to account for approximately 10% of all breast cancer cases. In addition, an estimated 15-20% of those affected by breast cancer have a positive family history.
Despite the fact that BRCA1 and BRCA2 are the two most significant genes in hereditary breast cancer predisposition, twenty years of analysis has highlighted the fact, that mutations in these two highly penetrant genes, are only present in approximately 20% of high risk families.
Other genes, mutations in which are associated with high risk of breast cancer, were identified because of the strong association with familial cancer syndromes, in which breast cancer is one of the defining components.
Technological advances in molecular biology and especially DNA sequencing, commonly designated as “Next Generation Sequencing – NGS” have aided in the concentrated efforts to identify new genes responsible for the missing heritability, allowing the application of this knowledge in the diagnostic setting.
AIM
The aim of this study was to investigate the extent and nature of mutations in 26 genes implicated in hereditary cancer predisposition in families of Romanian descent.
MATERIALS & METHODS
In total, 297 Romanian families have been analyzed by our group in the past three years.
Genomic DNA was enriched for targeted regions of 26 genes involved in hereditary predisposition to cancer (ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM (only intron 8, exon 9 and 3'UTR), FAM175A, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, XRCC2). Sequencing was carried out using the Illumina NGS technology. Reads were aligned to the reference sequence (GRCh38), and sequence changes were identified and interpreted in the context of a single clinically relevant transcript. The presence of large genomic rearrangements was investigated by use of MLPA. All clinically significant observations were confirmed by orthogonal technologies.
RESULTS
In total, a pathogenic mutation was identified in 79 of the 297 families (26.6%) analyzed. Clinically significant mutations were identified in 17 of the genes included in the panel. The most commonly mutated genes in the Romanian population were BRCA1 and BRCA2, accounting for 50% of the mutations identified, followed by PALB2 (12%), CHEK2 (9.4%) and ATM, NBN and RAD50 which accounted for 3.5% of the mutations each. Of note is that 7 of the 79 affected families (8.8%) carried clinically significant mutations in two different genes.
CONCLUSIONS
Our results support the clinical significance of analysis of a panel of genes involved in hereditary cancer predisposition. In this series of patients, analysis of this panel allowed for the identification of 14% additional pathogenic variants. This is especially true in those cases where more than one pathogenic variant was identified.
Citation Format: Tsoulos N, Apessos A, Agiannitopoulos K, Pepe G, Tsaousis G, Kambouri S, Eniu DT, Ungureanu A, Banu E, Ciule L, Blidaru A, Chiorean A, Stanculeanu DL, Mateescu D, Nasioulas G. Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-03-03.
Collapse
Affiliation(s)
- N Tsoulos
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - A Apessos
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - K Agiannitopoulos
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - G Pepe
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - G Tsaousis
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - S Kambouri
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - DT Eniu
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - A Ungureanu
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - E Banu
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - L Ciule
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - A Blidaru
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - A Chiorean
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - DL Stanculeanu
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - D Mateescu
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| | - G Nasioulas
- GeneKor M.S.A, Athens, Attiki, Greece; Institutul Oncologic Prof. Dr. I. Chiricuta, CLUJ, Romania; Amethyst Radiotherapy, Cluj-Napoca, Romania; Spitalul Sfantul Constantin, Brasov, Romania; Spitalul Clinic Judetean de Urgenta, Cluj-Napoca, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania; Regina Maria, Bucuresti, Romania
| |
Collapse
|
19
|
Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG. Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614530] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
SummaryElevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU × 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%, p<0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p<0.0001).After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p<0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/105 monocytes to 86.1 U/105 monocytes, 28-320 U/105 monocytes; - 38% and -55% respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ ml; +70%, p<0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.
Collapse
|
20
|
Sollini M, Cozzi L, Pepe G, Antunovic L, Lania A, Di Tommaso L, Magnoni P, Erba PA, Kirienko M. [ 18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results. Eur J Hybrid Imaging 2017; 1:3. [PMID: 29782578 PMCID: PMC5954705 DOI: 10.1186/s41824-017-0009-8] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 09/01/2017] [Indexed: 02/08/2023] Open
Abstract
Background significance of incidental thyroid 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake on positron emission tomography/computed tomography (PET/CT) scans remains controversial. We aimed to evaluate the ability of [18F]FDG-PET/CT texture analysis to predict final diagnosis in thyroid incidentaloma. Methods We retrospectively evaluated medical records of all patients who performed a [18F]FDG-PET/CT from January 2012 to October 2016. Those patients who presented a thyroid incidentaloma described in the medical records and performed a fine needle aspiration in our institution were considered for the analysis. Cytological and/or histological results were used as reference standard to define the final diagnosis. In case of negative cytology, the nodule was considered benign. In case of non-diagnostic or inconclusive results ultrasound, follow-up and further cytology/histology were used as final diagnosis. For suspected or positive cytological result, histology was used as reference standard. PET images were segmented using a General Electric AW workstation running PET VCAR software (GE Healthcare, Waukesha, WI, USA) settled with a threshold of 40% SUVmax. LifeX software (http://www.lifexsoft.org) was used to perform texture analysis. Statistical analysis was performed with R package (https://www.r-project.org). Results We identified 55 patients with incidental thyroid [18F]FDG uptake. Five patients were excluded from the analysis because a final diagnosis was not available. Thirty-two out of 50 patients had benign nodules while in 18/50 cases a malignancy (primary thyroid cancer = 15, metastases = 3) was diagnosed. Conventional PET parameters and histogram-based features were calculated for all 50 patients, while other matrices-based features were available for 28/50 patients. SUVmax and skewness resulted significantly different in benign and malignant nodules (p = 0.01 and = 0.02, respectively). Using ROC analysis, seven features were identified as potential predictors. Among all the textural features tested, skewness showed the best area under the curve (= 0.66). SUV-based parameters resulted in the highest specificity while MTV, TLG, skewness and kurtosis, as well as correlationGLCM resulted better in sensitivity. Conclusions [18F]FDG-PET/CT texture analysis seems to be a promising approach to stratify the patients with thyroid incidentaloma identified on PET scans, with respect to the risk of the diagnosis of a malignant thyroid nodule and thus, could refine the selection of the patients to be referred for cytology.
Collapse
Affiliation(s)
- M Sollini
- 1Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy
| | - L Cozzi
- 2Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy.,1Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy
| | - G Pepe
- 3Nuclear Medicine, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy
| | - L Antunovic
- 3Nuclear Medicine, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy
| | - A Lania
- 1Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy.,4Endocrinology, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy
| | - L Di Tommaso
- 1Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy.,5Pathology, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy
| | - P Magnoni
- 6Ultrasound Service, Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy
| | - P A Erba
- 7Regional Center of Nuclear Medicine, University of Pisa, via Roma 55, 56025 Pisa, Italy
| | - M Kirienko
- 1Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy
| |
Collapse
|
21
|
Zanon S, Pircher C, Chiaravalle M, Macchini M, Peretti U, Balzano G, Passoni P, Nicoletti R, Arcidiacono P, Pepe G, Doglioni C, Romi S, Gritti E, Falconi M, Gianni L, Reni M. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
La Greca A, Di Grezia M, Magalini S, Di Giorgio A, Lodoli C, Di Flumeri G, Cozza V, Pepe G, Foco M, Bossola M, Gui D. Comparison of cholecystectomy and percutaneous cholecystostomy in acute cholecystitis: results of a retrospective study. Eur Rev Med Pharmacol Sci 2017; 21:4668-4674. [PMID: 29131247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To retrospectively compare the clinical outcomes of percutaneous cholecystostomy (PC) and cholecystectomy in patients with acute cholecystitis admitted to an urban University Hospital. PATIENTS AND METHODS We studied 646 patients with acute cholecystitis. Ninety patients had placement of a PC at their index hospitalization, and 556 underwent cholecystectomy. Of the 90 patients with PC, 13 underwent subsequent elective cholecystectomy. RESULTS Overall, in-hospital mortality and postoperative complications were significantly higher in patients who received PC than in those who underwent cholecystectomy. In the ASA score 1-2 group, patients with PC were significantly older and had a longer postoperative stay while their mortality and morbidity were similar to patients who underwent cholecystectomy. In patients with ASA score of 3, PC and cholecystectomy did not differ significantly for demographic variables and clinical outcomes such as hospital stay, in-hospital mortality, postoperative complications and distribution of complications according to the classification of Clavien-Dildo. In mild, moderate, and severe cholecystitis, patients who underwent PC were significantly older than those who received cholecystectomy. In general, in mild, moderate and severe cholecystitis, the clinical outcomes did not differ significantly between patients who received PC and cholecystectomy. Morbidity was higher in patients with mild cholecystitis who underwent PC. Of the 77 patients dismissed from the hospital with drainage, 12 (15.6%) developed biliary complications and 5 needed substitutions of the drainage itself. CONCLUSIONS PC does not offer advantages compared to cholecystectomy in the treatment of acute cholecystitis. Its routine use is therefore questioned. There is need of an adequate, randomized study that compares PC and cholecystectomy in high-risk patients with moderate-severe cholecystitis.
Collapse
Affiliation(s)
- A La Greca
- Department of Emergency Surgery, University Hospital Foundation "Agostino Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Reni M, Zanon S, Pircher C, Chiaravalli M, Macchini M, Peretti U, Mazza E, Balzano G, Passoni P, Nicoletti R, Arcidiacono P, Pepe G, Doglioni C, Romi S, Ceraulo D, Falconi M, Gianni L. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Magalini S, Pepe G, Cozza V, Tilli P, La Greca A, Longo F, Gui D. Negative pressure wound therapy (NPWT) in duodenal breakdown fistulas: negative pressure fistula therapy (NPFT)? Eur Rev Med Pharmacol Sci 2017; 21:2452-2457. [PMID: 28617541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To describe for the first time in literature the specific methodology of use of negative pressure wound therapy (NPWT) for duodenal fistula through clinical cases. The constant increase of use of NPWT for complex surgical situations imposes tailored previously undescribed solutions for the technique. PATIENTS AND METHODS Herein, three cases of high output duodenal fistula successfully treated with Negative Pressure Wound Therapy (NPWT) are reported. The technical details for the application of NPWT to these fistulas are discussed and described. RESULTS All three patients recovered without the necessity of further surgical operations. CONCLUSIONS When using NPWT, management of high-output duodenal fistulas must rely on some degree of customization of the aspiration systems. The aim of the procedure is to put under depression the duodenal hole and surrounding tissues "all in one" and not to separate the complex wound in sectors as usually indicated. We suggest calling this technique Negative Pressure Fistula Therapy.
Collapse
Affiliation(s)
- S Magalini
- Emergency Surgery Department, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, School of Medicine, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Mirijello A, Pepe G, Zampiello P, Manfrini A. Ischemic Stroke After Wasp Sting: Another Manifestation of Kounis Syndrome? J Emerg Med 2017; 52:e215. [PMID: 28256353 DOI: 10.1016/j.jemermed.2016.09.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Accepted: 09/08/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Antonio Mirijello
- Department of Emergency Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy
| | - Gaetano Pepe
- Department of Emergency Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy
| | - Patrizio Zampiello
- Department of Emergency Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy
| | - Antonio Manfrini
- Department of Emergency Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy
| |
Collapse
|
26
|
Gui D, Cozza V, Pepe G, Di Grezia M, La Greca A, Magalini S. Present and future of emergency surgery as independent specialty in Italy: is the rescue surgery turning the underdog into a hero? Eur Rev Med Pharmacol Sci 2017; 21:899-902. [PMID: 28272689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- D Gui
- Department of Emergency Surgery, Catholic University of the Sacred Heart, School of Medicine, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
27
|
Terzoudi GI, Pantelias G, Darroudi F, Barszczewska K, Buraczewska I, Depuydt J, Georgieva D, Hadjidekova V, Hatzi VI, Karachristou I, Karakosta M, Meschini R, M'Kacher R, Montoro A, Palitti F, Pantelias A, Pepe G, Ricoul M, Sabatier L, Sebastià N, Sommer S, Vral A, Zafiropoulos D, Wojcik A. Dose assessment intercomparisons within the RENEB network using G 0-lymphocyte prematurely condensed chromosomes (PCC assay). Int J Radiat Biol 2016; 93:48-57. [PMID: 27813725 DOI: 10.1080/09553002.2016.1234725] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE Dose assessment intercomparisons within the RENEB network were performed for triage biodosimetry analyzing G0-lymphocyte PCC for harmonization, standardization and optimization of the PCC assay. MATERIALS AND METHODS Comparative analysis among different partners for dose assessment included shipment of PCC-slides and captured images to construct dose-response curves for up to 6 Gy γ-rays. Accident simulation exercises were performed to assess the suitability of the PCC assay by detecting speed of analysis and minimum number of cells required for categorization of potentially exposed individuals. RESULTS Calibration data based on Giemsa-stained fragments in excess of 46 PCC were obtained by different partners using galleries of PCC images for each dose-point. Mean values derived from all scores yielded a linear dose-response with approximately 4 excess-fragments/cell/Gy. To unify scoring criteria, exercises were carried out using coded PCC-slides and/or coded irradiated blood samples. Analysis of samples received 24 h post-exposure was successfully performed using Giemsa staining (1 excess-fragment/cell/Gy) or centromere/telomere FISH-staining for dicentrics. CONCLUSIONS Dose assessments by RENEB partners using appropriate calibration curves were mostly in good agreement. The PCC assay is quick and reliable for whole- or partial-body triage biodosimetry by scoring excess-fragments or dicentrics in G0-lymphocytes. Particularly, analysis of Giemsa-stained excess PCC-fragments is simple, inexpensive and its automation could increase throughput and scoring objectivity of the PCC assay.
Collapse
Affiliation(s)
- Georgia I Terzoudi
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Gabriel Pantelias
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Firouz Darroudi
- b Leiden University Medical Centre , Department of Toxicogenetics , Leiden , The Netherlands
| | - Katarzyna Barszczewska
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | | | - Julie Depuydt
- d Faculty of Medicine and Health Sciences , Universiteit Gent , Gent , Belgium
| | - Dimka Georgieva
- e National Center for Radiobiology and Radiation Protection , Sofia , Bulgaria
| | - Valeria Hadjidekova
- e National Center for Radiobiology and Radiation Protection , Sofia , Bulgaria
| | - Vasiliki I Hatzi
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Ioanna Karachristou
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Maria Karakosta
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Roberta Meschini
- f Department of Ecological and Biological Sciences , University of Tuscia , Viterbo , Italy
| | - Radhia M'Kacher
- g PROCyTOX, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses, Université Paris-Saclay , France
| | - Alegria Montoro
- h Hospital Universitario y Politécnico La Fe , Valencia , Spain
| | - Fabrizio Palitti
- f Department of Ecological and Biological Sciences , University of Tuscia , Viterbo , Italy
| | - Antonio Pantelias
- a National Centre for Scientific Research "Demokritos" , Health Physics, Radiobiology & Cytogenetics Laboratory , Athens , Greece
| | - Gaetano Pepe
- f Department of Ecological and Biological Sciences , University of Tuscia , Viterbo , Italy
| | - Michelle Ricoul
- g PROCyTOX, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses, Université Paris-Saclay , France
| | - Laure Sabatier
- g PROCyTOX, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses, Université Paris-Saclay , France
| | | | - Sylwester Sommer
- c Institut of Nuclear Chemistry and Technology , Warsaw , Poland
| | - Anne Vral
- d Faculty of Medicine and Health Sciences , Universiteit Gent , Gent , Belgium
| | | | - Andrzej Wojcik
- j Stockholm University, Institute Molecular Biosciences , Stockholm , Sweden.,k Institute for Biology, Jan Kochanowski University , Kielce , Poland
| |
Collapse
|
28
|
Reni M, Zanon S, Balzano G, Passoni P, Costantino A, Pircher C, Chiaravalli M, Nicoletti R, Arcidiacono P, Pepe G, Crippa S, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.73] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
|
29
|
Mirijello A, Pepe G, Zampiello P, Criconia GM, Mendola A, Manfrini A. A Male Patient with Syncope, Anaphylaxis, and ST-Elevation: Hepatic and Cardiac Echinococcosis Presenting with Kounis Syndrome. J Emerg Med 2016; 51:e73-e77. [DOI: 10.1016/j.jemermed.2016.06.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 03/12/2016] [Accepted: 06/04/2016] [Indexed: 11/29/2022]
|
30
|
Reni M, Zanon S, Balzano G, Passoni P, Costantino A, Pircher C, Chiaravalli M, Nicoletti R, Arcidiacono P, Pepe G, Crippa S, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Ainsbury E, Badie C, Barnard S, Manning G, Moquet J, Abend M, Antunes AC, Barrios L, Bassinet C, Beinke C, Bortolin E, Bossin L, Bricknell C, Brzoska K, Buraczewska I, Castaño CH, Čemusová Z, Christiansson M, Cordero SM, Cosler G, Monaca SD, Desangles F, Discher M, Dominguez I, Doucha-Senf S, Eakins J, Fattibene P, Filippi S, Frenzel M, Georgieva D, Gregoire E, Guogyte K, Hadjidekova V, Hadjiiska L, Hristova R, Karakosta M, Kis E, Kriehuber R, Lee J, Lloyd D, Lumniczky K, Lyng F, Macaeva E, Majewski M, Vanda Martins S, McKeever SW, Meade A, Medipally D, Meschini R, M’kacher R, Gil OM, Montero A, Moreno M, Noditi M, Oestreicher U, Oskamp D, Palitti F, Palma V, Pantelias G, Pateux J, Patrono C, Pepe G, Port M, Prieto MJ, Quattrini MC, Quintens R, Ricoul M, Roy L, Sabatier L, Sebastià N, Sholom S, Sommer S, Staynova A, Strunz S, Terzoudi G, Testa A, Trompier F, Valente M, Hoey OV, Veronese I, Wojcik A, Woda C. Integration of new biological and physical retrospective dosimetry methods into EU emergency response plans – joint RENEB and EURADOS inter-laboratory comparisons. Int J Radiat Biol 2016; 93:99-109. [DOI: 10.1080/09553002.2016.1206233] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Elizabeth Ainsbury
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Christophe Badie
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Stephen Barnard
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Grainne Manning
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Jayne Moquet
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Michael Abend
- Bundeswehr Institute of Radiobiology (BIR), Munich, Germany
| | - Ana Catarina Antunes
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | | | - Celine Bassinet
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Christina Beinke
- Bundeswehr Institute of Radiobiology affiliated to the University of Ulm (UULM), Munich, Germany
| | | | - Lily Bossin
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
- Durham University (DUR), Durham, UK
| | - Clare Bricknell
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Kamil Brzoska
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | - Iwona Buraczewska
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | | | - Zina Čemusová
- Státní ústav radiační ochrany (SÚRO), Prague, Czech Republic
| | | | | | - Guillaume Cosler
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | | | | | - Michael Discher
- Salzburg University Department of Geography and Geology, Salzburg, Austria
| | | | | | - Jon Eakins
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | | | | | - Monika Frenzel
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Dimka Georgieva
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Eric Gregoire
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | | | | | | | - Rositsa Hristova
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Maria Karakosta
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Enikő Kis
- National Public Health Centre – National Research Institute for Radiobiology and Radiohygiene (NRIRR), Hungary
| | - Ralf Kriehuber
- Radiation Biology Unit Forschungszentrum Jülich GmbH (FzJ), Jülich, Germany
| | - Jungil Lee
- Korea Atomic Energy Research Institute (KAERI), Daejeon, South Korea
| | - David Lloyd
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Katalin Lumniczky
- National Public Health Centre – National Research Institute for Radiobiology and Radiohygiene (NRIRR), Hungary
| | - Fiona Lyng
- Dublin Institute of Technology (DIT), Dublin, Ireland
| | - Ellina Macaeva
- Belgian Nuclear Research Centre (SCK-CEN), Mol, Belgium
- Ghent University (GU), Ghent, Belgium
| | | | - S. Vanda Martins
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | | | - Aidan Meade
- Dublin Institute of Technology (DIT), Dublin, Ireland
| | | | | | - Radhia M’kacher
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Octávia Monteiro Gil
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | - Alegria Montero
- Radiation Protection Service, IIS La Fe, Health Research Institute (LAFE), Spain
| | - Mercedes Moreno
- Laboratorio de Dosimetría Biológica, Servicio de Oncología Radioterápica, Hospital General Universitario Gregorio Marañón (SERMAS), Spain
| | | | - Ursula Oestreicher
- Bundesamt fuer Strahlenschutz (BfS), Department Radiation Protection and Health, Neuherberg, Germany
| | - Dominik Oskamp
- Radiation Biology Unit Forschungszentrum Jülich GmbH (FzJ), Jülich, Germany
| | | | - Valentina Palma
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Gabriel Pantelias
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Jerome Pateux
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | - Clarice Patrono
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Gaetano Pepe
- Università degli Studi della Tuscia (UNITUS), Italy
| | - Matthias Port
- Bundeswehr Institute of Radiobiology (BIR), Munich, Germany
| | - María Jesús Prieto
- Laboratorio de Dosimetría Biológica, Servicio de Oncología Radioterápica, Hospital General Universitario Gregorio Marañón (SERMAS), Spain
| | | | - Roel Quintens
- Belgian Nuclear Research Centre (SCK-CEN), Mol, Belgium
| | - Michelle Ricoul
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Laurence Roy
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Laure Sabatier
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Natividad Sebastià
- Radiation Protection Service, IIS La Fe, Health Research Institute (LAFE), Spain
| | | | - Sylwester Sommer
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | - Albena Staynova
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Sonja Strunz
- Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany
| | - Georgia Terzoudi
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Antonella Testa
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Francois Trompier
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Marco Valente
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | | | - Ivan Veronese
- Università degli Studi di Milano (UNIMI), Milano, Italy
| | | | - Clemens Woda
- Helmholtz Zentrum München (HMGU), Neuherberg, Germany
| |
Collapse
|
32
|
Nazerian P, Gigli C, Pavellini A, Ermini FR, Pepe G, Vanni S, Grifoni S. Diagnostic performance of focused cardiac ultrasound performed by emergency physicians for the assessment of ascending aorta dilatation and aneurysm. Crit Ultrasound J 2015. [DOI: 10.1186/2036-7902-7-s1-a12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
33
|
Meschini R, Berni A, Filippi S, Pepe G, Grossi MR, Natarajan AT, Palitti F. The micronucleus assay in mammalian cells in vitro to assess health benefits of various phytochemicals. Mutat Res Genet Toxicol Environ Mutagen 2015; 793:79-85. [PMID: 26520376 DOI: 10.1016/j.mrgentox.2015.06.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 06/28/2015] [Indexed: 12/24/2022]
Abstract
We evaluated the protective effects of Gentiana lutea extracts (GLEx) and 6-Gingerol (6-G) on clastogenicity of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and 7,12-dimethylbenz(α) anthracene (DMBA) in vitro on HepG2 cells using the frequencies of induced micronuclei (MN) as the end point. Pre-, post- and simultaneous treatments with GLEx or 6-G and the carcinogens were carried out. Both GLEx post- and simultaneous treatments reduced the frequencies of MN induced by MNNG and DMBA. Probably this effect is due to an increase of cytostasis and a physico-chemical interaction between GLEx and DMBA under simultaneous treatment. Pre- and simultaneous treatments with 6-G significantly reduced the yield of MNNG-induced micronuclei without affecting % of cytostasis. Simultaneous treatment with 6-G plus DMBA resulted in reduction in the frequency of MN and an increase in cytotoxicity compared to sample treated alone with DMBA, whereas a post-treatment, caused a significant decrease in the yield of MN compared with DMBA alone without any cytotoxic effect. These results are compared with our earlier data obtained in the same system with other phytochemicals. It is concluded that for a critical evaluation of the protective effects of phytochemicals, both the influence on the induced MN and induced cytostasis have to be considered.
Collapse
Affiliation(s)
- Roberta Meschini
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy.
| | - Andrea Berni
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| | - Silvia Filippi
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| | - Gaetano Pepe
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| | - Maria Rosaria Grossi
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| | - Adayapalam T Natarajan
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| | - Fabrizio Palitti
- Department of Ecological and Biological Sciences, University of Tuscia, Via San Camillo de Lellis snc, 01100 Viterbo, Italy
| |
Collapse
|
34
|
Mosesso P, Pepe G, Ottavianelli A, Schinoppi A, Cinelli S. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations. Mutat Res Genet Toxicol Environ Mutagen 2015; 793:14-8. [PMID: 26520368 DOI: 10.1016/j.mrgentox.2015.06.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 06/09/2015] [Indexed: 11/17/2022]
Abstract
ICRF-187 (Cardioxane™, Chiron) is a catalytic inhibitor of DNA topoisomerase II (Topo II), proposed to act by blocking Topo II-mediated DNA cleavage without stabilizing DNA-Topo II-"cleavable complexes". In this study ICRF-187 was used to evaluate the potential involvement of DNA topoisomerase II in the formation of the radiation-induced chromosome-type aberrations in the G0 phase of the cell cycle in human lymphocytes from three healthy male donors. This is based on many evidences that DNA topoisomerases are involved in DNA recombination, mainly of illegitimate type (non-homologous) both in vitro and in vivo. The results obtained clearly indicated that ICRF-187 did not induce per se any chromosomal damage. When challenged with the non-catalytic Topo II poison VP-16 (etoposide), which acts by stabilizing the "cleavable complex" generating "protein concealed" DSB's and thus chromosomal aberrations, it completely abolished the significant induction of chromosome-type aberrations and formation of dicentric chromosomes. This indicates that ICRF-187 acts effectively as catalytic inhibitor of Topo II. On the other hand, when X-ray treatments were challenged with ICRF-187 using experimental conditions as for VP-16 treatments, no modification of the incidence of chromosome-type aberrations and dicentric chromosomes was observed. On this basis, we conclude that Topo II is not involved in the formation of X-ray-induced chromosome-type aberrations and dicentric chromosomes in human lymphocytes in the G0 phase of the cell cycle.
Collapse
Affiliation(s)
- P Mosesso
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, Largo dell'Università s.n.c., 01100 Viterbo, Italy.
| | - G Pepe
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, Largo dell'Università s.n.c., 01100 Viterbo, Italy
| | - A Ottavianelli
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, Largo dell'Università s.n.c., 01100 Viterbo, Italy
| | - A Schinoppi
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, Largo dell'Università s.n.c., 01100 Viterbo, Italy
| | - S Cinelli
- Research Toxicology Centre, Via Tito Speri 12/14, 00040, Pomezia, Roma, Italy
| |
Collapse
|
35
|
Frongillo F, Avolio AW, Nure E, Mulè A, Pepe G, Magalini SC, Agnes S. Quantification of degree of steatosis in extended criteria donor grafts with standardized histologic techniques: implications for graft survival. Transplant Proc 2014; 41:1268-72. [PMID: 19460535 DOI: 10.1016/j.transproceed.2009.03.096] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The gap between the availability of livers from organ donors and the increased demand has led many centers to apply strategies to reduce this deficit. Splitting of cadaveric organs for use in 2 recipients; domino transplantation; and organs from living donors, non-heart-beating donors, and extended-criteria donors (ECDs) are all currently used in orthotopic liver transplantation (OLT). Fatty changes in the donor liver are a risk factor for poor function after OLT; however, the presence of steatosis, frequently present in livers from ECDs, does not exclude the use of these organs. Since January 2000 at our institution, we observed 39 steatotic grafts that were stratified istologically as follows: low steatosis, 5% to 15%; mild steatosis, 16% to 30%; moderate steatosis, 31% to 60%; and severe steatosis (>60%). Histologic techniques can enable identification of the type of fatty change as macrovesicular and microvesicular. These alterations have different effects on primary nonfunction and primary dysfunction. Fifteen grafts, all with severe or moderate, macrovesicular changes were discarded. Twenty-four fatty grafts with low to moderate steatosis were utilized for transplant. Sections from 2 liver biopsies (1 wedge in the left lobe and 1 needle in the right lobe) were stained with hematoxylin-eosin, Masson trichrome, Gomori reticulin, and oil red O. The OLT was performed only in patients with a MELD (Model for End-Stage Liver Disease) score lower than 27. The rate of primary dysfunction was 12.5%, and of primary nonfunction 8.4%. The 6-month graft survival for all fatty livers was 80%. We encourage the careful use of grafts with low to moderate steatosis in recipients without additional risks.
Collapse
Affiliation(s)
- F Frongillo
- Department of Surgery, U.O. Chirurgia Sostitutiva, Policlinico "A. Gemelli", Catholic University, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
36
|
Reni M, Belli C, Balzano G, Cereda S, Nicoletti R, Pepe G, Sessa C, Cappio S, Doglioni C, Palazzo V, Ceraulo D, Gianni L. Phase Ib Trial of Nab-Paclitaxel Plus Gemcitabine, Capecitabine, and Cisplatin (Paxg Regimen) in Patients with Stage III Pancreatic Adenocarcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Melchiorre D, Pratelli E, Torricelli E, Sofi F, Abbate R, Matucci-Cerinic M, Gensini G, Pepe G. AB0958 Tendon's Involvement in Marfan Syndrome: Ultrasound Evaluation. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Pepe G, Magalini S, Callari C, Persiani R, Lodoli C, Gui D. Vacuum Assisted Closure (VAC) therapyTM as a swiss knife multi-tool for enteric fistula closure: tips and tricks: a pilot study. Eur Rev Med Pharmacol Sci 2014; 18:2527-2532. [PMID: 25268100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE Enterocutaneous fistulas (ECFs) are an uncommon surgical problem, but they are characterized by a difficult management. Vacuum-assisted closure (VAC) therapy is a method utilized for chronic and traumatic wound healing. At first, VAC therapy had been contraindicated in the treatment of intestinal fistulas, but as time went by, VAC therapy revealed itself to be a "Swiss knife multi-tool". This paper presents some clinical cases of enterocutaneous (ECF) and enteroatmospheric fistulas (EAF) treated with VAC therapy™. MATERIALS AND METHODS The history of 8 patients treated for complex fistulas was revised. Four of them presented with enterocutaneous and four with enteroatmospheric fistulas. All were treated with VAC therapy with variations elaborated to help in accelerated closure of intestinal wall lesions. RESULTS Four out of four ECFs closed spontaneously. In the EAF group, in three cases the fistula turned slowly into an entero-cutaneous fistula, and in one out of four it closed spontaneously. The mean length of VAC therapy™ was 35.5 days and that of spontaneous closure was 36.4 days. CONCLUSIONS The results of our study encourage the use of VAC therapy™ for the treatment of enterocutaneous fistulas. VAC therapy™ use has a double therapeutic value: (1) it promotes the healing of the skin and allows also the management of EAFs; (2) in selected cases, those in which it is possible to create a deep fistula tract ("well") it is possible to assist to a complete healing with closure of the ECFs.
Collapse
Affiliation(s)
- G Pepe
- Emergency Surgery Unit, Department of Surgery, Catholic University of the Sacred Heart, Gemelli Polyclinic, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
39
|
Grossi MR, Berni A, Pepe G, Filippi S, Meschini R, Papeschi C, Natarajan AT, Palitti F. Evaluation of the effects of ellagic acid (EA) on 7,12-dimethylbenz(α) anthracene (DMBA) induced micronuclei in mammalian cells in vitro and in vivo. Toxicol Lett 2014; 224:240-5. [DOI: 10.1016/j.toxlet.2013.10.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 10/10/2013] [Accepted: 10/11/2013] [Indexed: 11/26/2022]
|
40
|
Magalini S, Pepe G, Panunzi S, De Gaetano A, Abatini C, Di Giorgio A, Foco M, Gui D. Observational study on preoperative surgical field disinfection: povidone-iodine and chlorhexidine-alcohol. Eur Rev Med Pharmacol Sci 2013; 17:3367-3375. [PMID: 24379069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND AND OBJECTIVES Surgical site infection (SSI) rate is reported to range around 16%. Preoperative skin disinfection is keystone for SSI reduction. Chlorhexidine-alcohol has been reported to be more effective than Povidone-iodine (PVI). However, in many countries established habits and the inferior costs of PVI restrain the employment of chlorhexidine disinfection kits (ChloraPrep®) for the preparation of the surgical field. MATERIALS AND METHODS The costs of surgical field preparation in clean-contaminated surgery utilizing PVI (Betadine) and chlorhexidine alcohol and the evaluation of surgeon compliance and satisfaction, were studied by a observational study on 50 surgical operations in which surgical field was prepared with PVI checking established guidelines, and on 50 surgical operations in which chlorhexidine-alcohol (ChloraPrep) was employed. The use of auxiliary material was tabulated as well as the timing of the phases of disinfection and the surgeon's opinions. RESULTS The use of auxiliary material (gloves, gauzes, paper towels, surgical instruments, small swabs for umbilical cleaning) is associated with the type of disinfectant, with major use of auxiliary materials recorded in PVI disinfection. PVI disinfection does not follow stringent guidelines, in particular waiting for the disinfectant to dry. PVI guidelines are more demanding than those relative to ChloraPrep. The time necessary for the preparation of the field is significantly longer for PVI. Auxiliary material and guideline compliance must be taken into account when calculating costs; the former are direct costs (even though marginal) and the latter can determine major infective risk. CONCLUSIONS Chlorhexidine in kits is easier and faster to use than PVI, requires less auxiliary material and has been shown previously to reduce SSI in clean contaminated surgery.
Collapse
Affiliation(s)
- S Magalini
- Acute Care and Trauma Surgery, Department of Surgery, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Nazerian P, Vanni S, Gigli C, Lamorte A, Zanobetti MG, Volpicelli G, Ciavattone A, Buccioni T, Pepe G, Grifoni S. Point of care multi-organ ultrasonography is an accurate tool to diagnose pulmonary embolism in the emergency department and may reduce the number of patients that undergo computed tomography. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Pepe G, Contri S, Castelli M, Pavellini A, Nazerian P, Ticali P, Vanni S, Grifoni S. Hypertensive Crises in the Emergency department: true story or chasing the white rabbit? Prevalence and clinical picture in patients with severe elevations of arterial blood pressure. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Angeletti D, Sebbio C, Carere C, Cimmaruta R, Nascetti G, Pepe G, Mosesso P. Terrestrial gastropods (Helix spp) as sentinels of primary DNA damage for biomonitoring purposes: a validation study. Environ Mol Mutagen 2013; 54:204-212. [PMID: 23444166 DOI: 10.1002/em.21766] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Revised: 01/18/2013] [Accepted: 01/18/2013] [Indexed: 06/01/2023]
Abstract
We validated the alkaline comet assay in two species of land snail (Helix aspersa and Helix vermiculata) to test their suitability as sentinels for primary DNA damage in polluted environments. The study was conducted under the framework of a biomonitoring program for a power station in Central Italy that had recently been converted from oil to coal-fired plant. After optimizing test conditions, the comet assay was used to measure the % Tail DNA induced by in vitro exposure of hemocytes to different concentrations of a reactive oxygen species (H2 O2 ). The treatment induced significant increases in this parameter with a concentration effect, indicating the effectiveness of the assay in snail hemocytes. After evaluating possible differences between the two species, we sampled them in three field sites at different distances from the power station, and in two reference sites assumed to have low or no levels of pollution. No species differences emerged. Percent Tail DNA values in snails from the sites near the power station were higher than those from control sites. An inverse correlation emerged between % Tail DNA and distance from the power station, suggesting that the primary DNA damage decreased as distance increased away from the pollution source. Detection of a gradient of heavy metal concentration in snail tissues suggests that these pollutants are a potential cause of the observed pattern. The comet assay appears to be a suitable assay and Helix spp. populations suitable sentinels to detect the genotoxic impact of pollutants.
Collapse
Affiliation(s)
- Dario Angeletti
- Department of Ecological and Biological Sciences, University of Tuscia, Viterbo, Italy.
| | | | | | | | | | | | | |
Collapse
|
44
|
Frongillo F, Grossi U, Avolio AW, Sganga G, Nure E, Pepe G, Bianco G, Lirosi MC, Agnes S. Factors predicting ischemic-type biliary lesions (ITBLs) after liver transplantation. Transplant Proc 2013; 44:2002-4. [PMID: 22974892 DOI: 10.1016/j.transproceed.2012.06.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Among biliary complications, ischemic-type biliary lesions (ITBLs) remain a major cause of morbidity in liver transplant recipients, significantly affecting the chance of survival of both patients and grafts. We retrospectively reviewed 10 years of prospectively collected donor and recipient data from April 2001 to April 2011. We evaluated the incidence of ITBL occurrence, exploring the possible predisposing factors, including donor and recipient data. Two hundred fifty-one grafts were harvested: 222 of them were transplanted at our institution, the remaining 29 (11.6%) discarded by our donor team as showing >40% macrovesicular steatosis. Mild-moderate (20%-40%) macrovesicular steatosis (P < .001) and cold ischemia time (P = .048) significantly increased the risk of ITBL, also as an independent risk factor after multivariate analysis.
Collapse
Affiliation(s)
- F Frongillo
- Department of General Surgery and Organ Transplantation, Catholic University of the Sacred Heart, Policlinico A. Gemelli, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Sganga G, Pepe G, Cozza V, Nure E, Lirosi MC, Frongillo F, Grossi U, Bianco G, Agnes S. Anidulafungin--a new therapeutic option for Candida infections in liver transplantation. Transplant Proc 2013; 44:1982-5. [PMID: 22974887 DOI: 10.1016/j.transproceed.2012.06.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION In the last years, the incidence of Candida infections in liver transplant recipients has increased with still higher morbidity and mortality. Anidulafungin, a new echinocandin that does not interfere with cytochrome p450, shows no need for dosage adjustment based upon renal or hepatic function or weight. AIM To analyze tolerance to and microbiologic and clinical efficacy of Anidulafungin to treat Candida infections in liver transplant patients. MATERIALS AND METHODS This phase 3b, prospective, open-label, single-center study focused on liver transplant patients with a suspected and/or diagnosed Candida infection. The patients received Anidulafungin intravenously, optionally followed by oral therapy with azoles. The primary endpoint was the global response at the end of therapy; secondary endpoints were the efficacy of intravenous therapy, 90-day survival, as well as tolerance for and interaction with immunosuppresants. RESULTS We considered 42 consecutive liver recipients transplanted between 2009 and 2010 among whom 13 (31%) were recruited for the study and four patients were treated with Anidulafungin as empirical therapy, six as preemptive therapy, and three as targeted treatment for documented candidemia (7.1%). The immunosuppressive regimen consisted of tacrolimus and low dose of steroids. The Candida species were: C albicans (50%), C glabrata (12.5%), C parapsilosis (12.5%), C krusei (12.5%), C lusitaniae (6.2%), C tropicalis (6.2%), and multiple others (25%). The principle site of isolation was the bile (53.8%), followed by the bloodstream (23.1%), central venous catheters (15.4%), bronchoalveolar lavage (15.4%), peritoneum (7.7%), and other locations (7.7%). Two patients (15.4%) died of severe sepsis with multiple organ failure. There was no alteration of hepatic enzymes, indices of cholestasis or changes in immunosuppressant drug levels. CONCLUSION Anidulafungin was an effective, safe, and well-tolerated drug. There were neither toxic effects to the grafts or adverse interactions with immunosuppresants.
Collapse
Affiliation(s)
- G Sganga
- Department of Surgery, Division of General Surgery and Organ Transplantation, Catholic University of Rome, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Magalini S, Pepe G, Panunzi S, Spada PL, De Gaetano A, Gui D. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci 2012; 16:2136-2141. [PMID: 23280031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND AND OBJECTIVES Clostridium difficile infection (CDI) accounts for the majority of nosocomial cases of diarrhea, and with recent upsurge of multidrug-resistant strains, morbidity and mortality have increased. Data on clinical impact of CDI come mostly from Anglo-Saxon countries, while in Italy only two studies address the issue and no economic data exist on costs of CDI in the in hospital setting. A retrospective cross-sectional study with pharmacoeconomic analysis was performed on the CDI series of the Policlinico Gemelli of Rome, a major 1400 bed Hospital. PATIENTS AND METHODS The clinical charts of 133 patients in a 26 month period were reviewed. All costs of the involved resources were calculated and statistical analysis was carried out with means and standard deviations, and categorical variables as number and percentages. RESULTS The results show the significant sanitary costs of CDI in an Italian hospital setting. The cost analysis of the various elements (exams, imaging studies, therapies, etc.) shows that none independently influences the high cost burden of CDI, but that it is the simple length of hospital stay that represents the most important factor. CONCLUSIONS Prevention of CDI is the most cost-effective approach. The major break-through in cost reduction of CDI would be a therapeutical intervention or procedure that shortens hospital length of stay.
Collapse
Affiliation(s)
- S Magalini
- Department of Surgery, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
47
|
Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A. Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo. Mol Nutr Food Res 2012; 56:1363-74. [PMID: 22865590 DOI: 10.1002/mnfr.201200226] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2012] [Revised: 05/21/2012] [Accepted: 06/05/2012] [Indexed: 11/09/2022]
Abstract
SCOPE Furan is a potent hepatotoxicant and liver carcinogen in rodents. However, short-term tests for genotoxicity of furan are inconclusive. The aim of this study was to assess the potential of furan to covalently bind to DNA, and to assess furan genotoxicity in rats in vivo. MATERIALS AND METHODS Accelerator mass spectrometry was used to determine the (14) C-content in DNA following administration of [3,4-(14) C]-furan (0.1 and 2.0 mg/kg bw) to F344 rats. DNA damage, micronuclei, chromosomal aberrations, and sister chromatid exchanges were analyzed in F344 rats treated with furan for up to 28 days. CONCLUSION The (14) C-content in liver DNA was significantly increased in a dose-dependent manner, with mean concentrations of 7.9 ± 3.5 amol (14) C/μg DNA and 153.3 ± 100.2 amol (14) C/μg DNA, corresponding to 16.5 ± 7.4 and 325.2 ± 212.7 adducts/10(9) nucleotides at 0.1 and 2.0 mg/kg bw, respectively. There was no evidence for genotoxicity of furan in peripheral blood and bone marrow cells. However, a dose-related increase in the incidence of chromosomal aberrations in rat splenocytes and some indication of DNA damage in liver were observed. Collectively, results from this study indicate that furan may operate-at least in part-by a genotoxic mode of action.
Collapse
Affiliation(s)
- Carolin Neuwirth
- Department of Toxicology, University of Würzburg, Würzburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Mosesso P, Bohm L, Pepe G, Fiore M, Carpinelli A, Gäde G, Nagini S, Ottavianelli A, Degrassi F. Cytogenetic analyses of Azadirachtin reveal absence of genotoxicity but marked antiproliferative effects in human lymphocytes and CHO cells in vitro. Toxicol Lett 2012; 213:361-6. [PMID: 22885097 DOI: 10.1016/j.toxlet.2012.07.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 07/23/2012] [Accepted: 07/24/2012] [Indexed: 02/02/2023]
Abstract
In this work we have examined the genotoxic potential of the bioinsecticide Azadirachtin A (AZA) and its influence on cell proliferation on human lymphocytes and Chinese Hamster ovary (CHO) cells. AZA genotoxicity was assessed by the analysis of chromosomal aberrations and sister chromatid exchanges (SCEs) in the absence and presence of rat liver S9 metabolism. Primary DNA damage was also investigated by means of the comet assay. The results obtained clearly indicate that AZA is not genotoxic in mammalian cells. On the other hand, AZA proved to interfere with cell cycle progression as shown by modulation of frequencies of first (M1) and second division (M2) metaphases detected by 5-Bromo-2'-deoxyuridine labeling. Accumulation of M1 metaphases were more pronounced in human lymphocytes. In the transformed CHO cell line, however, significant increases of multinucleated interphases and polyploid cells were observed at long treatment time. At higher dose-levels, the incidence of polyploidy was close to 100%. Identification of spindle structure and number of centrosomes by fluorescent immunostaining with α- and γ-tubulin antibodies revealed aberrant mitoses exhibiting multipolar spindles with several centrosomal signals. These findings suggest that AZA can act either through a stabilizing activity of microtubules or by inhibition of Aurora A, since both mechanisms are able to generate genetically unstable polyploid cells with multipolar spindles and multinucleated interphases.
Collapse
Affiliation(s)
- Pasquale Mosesso
- Dipartimento di Scienze Ecologiche e Biologiche, Università degli Studi della Tuscia, Largo dell'Università, 01100 Viterbo, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Antunovic L, Franklin-Bezerra B, Rodari M, Pepe G, Chiti A. (99m)Tc-DTPA uptake in clear-cell renal carcinoma metastases. Rev Esp Med Nucl Imagen Mol 2012; 31:169-170. [PMID: 22811984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- L Antunovic
- Nuclear Medicine Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
| | | | | | | | | |
Collapse
|
50
|
Antunovic L, Franklin-Bezerra B, Rodari M, Pepe G, Chiti A. 99mTc-DTPA uptake in clear-cell renal carcinoma metastases. Rev Esp Med Nucl Imagen Mol 2012. [DOI: 10.1016/j.remnie.2012.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|